CASI Pharmaceuticals, Inc., a U.S. biopharmaceutical company, received approval from the China National Medical Products Administration (NMPA) for the Company’s Clinical Trial Application (CTA) for BI-1206, a first-in-class fully human monoclonal antibody (mAb) that targets FcγRIIB.   CASI is planning Phase 1 trials of BI-1206 as a single agent to evaluate the PK/safety profile and in combination with rituximab in NHL (mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma...